Injection mezlocillin sodium liposome and preparation method

Abstract

The invention relates to the technical field of medicine and discloses injection mezlocillin sodium liposome and a preparation method. The injection mezlocillin sodium liposome is powder-injection. Mezlocillin sodium is packed with liposome carriers formed by liposome framework materials containing antioxygen and a stabilizing agent so as to obtain freezing-dried preparation. The injection mezlocillin sodium liposome is composed of 1 part of the mezlocillin sodium, 2 parts to 13 parts of the liposome framework materials, 0.3 part to 5 parts of the stabilizing agent, 4 parts to 10 parts of a freezing-dried protection agent and 0.1 part to 2 parts of the antioxygen. The injection mezlocillin sodium liposome has the obvious advantages that the mezlocillin sodium is wrapped in the liposome, thereby resolving the problem of slight solubility and guaranteeing quality of products; and medicine carrier liposome is degraded in bodies, thereby having no toxicity and immunogenicity, effectively improving therapeutic indexes of medicine, reducing toxicity of the medicine and reducing side effects of allergy rate, drug resistance, cardiotoxicity and the like.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to mezlocillin sodium liposome for injection and a preparation method thereof. Background technique [0002] Mezloeillin Sodium is a high-efficiency benzazole penicillin antibiotic, which was discovered by German Bayer Company in 1968 when studying ampicillin a-aminophthalated derivatives. It was first listed in the Federal Republic of Germany in 1977. It was officially approved to be listed in the United States. Since the 1980s, it has been listed in the United States, Japan, Italy, the Netherlands, Switzerland and other countries. Mezlocillin is difficult to absorb from the gastrointestinal tract, and sodium salt is commonly used for parenteral administration at present; at the same time, during the clinical use of mezlocillin sodium, it is often difficult to dissolve and dissolve for a long time (the dissolution time in winter is even summer several times), seriously affecting ...

AI Technical Summary

Problems solved by technology

Mezlocillin is difficult to absorb from the gastrointestinal tract, and sodium salt is commonly used for parenteral administration at present; at the same time, during the clinical use of mezlocillin sodium, it is often difficult to dissolve and dissolve for a long time (the dissolution time in winter is even summer several times), seriously affecting its clinical work efficiency

Although at present, many manufacturers add excipients to improve the solubility of mezlocillin sodium during production, the effect is still not obvious. At the same time, increasing the excipients increases the clinical allergic reaction rate of mezlocillin, making it drug-resistant Significantly increased sex and cardiotoxicity

[0003] Aiming at the characteristics of poor solubility, allergy rate, drug resistance and high cardiotoxicity of existing mezlocillin sodium for injection, the present invention applies a new type of liposome to mezlocillin sodium injection preparations to solve the problem of mezlocillin sodium injection. The problem of the poor solubility of cillin sodium effectively reduces the problems of allergy rate, drug resistance and cardiotoxicity simultaneously, and achieves unexpected effects, thereby completing the present invention